Dishman Carbogen Amcis Limited completed the allotment of its Non-Convertible Debentures (NCD) issue on August 17, 2026. The company allotted 7,500 senior, secured, rated, listed, transferable, redeemable, and taxable debentures aggregating ₹75 crore through a private placement. This transaction finalizes the capital raise approved by the Board of Directors on August 12, 2026, strengthening the firm’s capital structure without equity dilution.

Allotment Details

The Management Committee of the Board of Directors approved the allotment during a meeting held on August 17, 2026. The committee commenced proceedings at 12:30 pm and concluded at 1:00 pm. The allotment was made at par for cash, adhering to the terms outlined in the general information document dated December 30, 2025, and the key information document dated August 13, 2026.

Security and Structure

The NCDs are secured with a 1.1x security cover. Primary security includes a first-ranking exclusive charge by way of mortgage created by Dishman Infrastructure Limited (DIL) over non-agriculture land located in Bavla, Ahmedabad. The mortgaged property comprises survey numbers 744, 740, 745, 288/3, 1381, 1379, 1401, and 1377/1, aggregating to 1,71,476 square meters. DIL has also issued an unconditional and irrevocable corporate guarantee in favor of the Debenture Trustee for the benefit of debenture holders. The security package further includes a demand promissory note and a letter of continuity.

Principal repayment will be executed via a bullet payment on maturity. There are no special rights, interests, or privileges attached to the instrument beyond those standard for such debt securities. The debentures are proposed to be listed on the Wholesale Debt Market Segment of BSE Limited.

Regulatory Compliance

The disclosure was made pursuant to Regulations 30 and 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This follows the earlier intimation under Regulations 29 and 50 dated August 7, 2026, and the board approval disclosure dated August 12, 2026. Shrima Gaurangbhai Dave, Company Secretary, signed the intimation letter addressed to the Department of Corporate Services at BSE Ltd. and the Listing Department at National Stock Exchange of India Ltd. The issuance complies with the SEBI Master Circular dated January 30, 2026.

Dishman Carbogen Amcis reported a significant deterioration in its financial performance for the first quarter of FY27, posting a consolidated net loss of ₹579 million. This marks a sharp reversal from the previous year, when the company recorded a net profit of ₹234 million in the same period. The swing to losses was primarily driven by the deferment of Contract Development and Manufacturing Organisation (CDMO) revenues and rising employee expenses.

Alongside the swing to losses, the company’s top-line growth stalled. Revenue for the quarter stood at ₹6,776 million, down 4.3% from ₹7,081 million recorded in the corresponding quarter of the prior fiscal year. The decline in revenue coincided with the emergence of the net loss, indicating pressure on the company’s bottom line despite relatively modest contraction in sales. Management attributed the revenue dip to customer-requested rescheduling of project deliverables worth approximately CHF 10 million to the second half of the financial year.

Segment Performance

The revenue contraction was concentrated in the CDMO segment, which is the company’s primary growth engine. CDMO revenue declined by 12.6% year-on-year to ₹5,344 million from ₹6,113 million. This segment contributed 79% of total revenue in Q1FY27, down from 83% in FY26. Conversely, the Marketable Molecules (MM) segment saw robust growth, with revenue increasing by 48% to ₹1,433 million from ₹968 million, driven largely by higher Cholesterol sales.

Margin Compression

EBITDA margin contracted sharply to 8.9% in Q1FY27, compared with 19.9% in Q1FY26. The absolute EBITDA fell by 57.3% to ₹601 million from ₹1,407 million. The margin compression in the CDMO segment was severe, dropping to 6.3% from 17.9%, as the cost base remained largely fixed while revenues were deferred. Additionally, a notional foreign exchange loss of INR 117.3 million impacted margins. The MM segment margin also declined to 18.6% from 32.4%, though management noted these levels are in line with full-year FY26 margins.

Operating expenses rose during the quarter. Employee expenses increased by 10.6% to ₹3,891 million, while Cost of Goods Sold (COGS) rose by 16.5% to ₹1,142 million. Depreciation and amortization charges increased by 11.5% to ₹907 million. Finance costs decreased slightly by 13.3% to ₹371 million.

What the Numbers Show

The data reveals a structural vulnerability in the company’s cost structure during periods of revenue volatility. While revenue declined by only 4.3%, EBITDA plummeted by 57.3%. This disproportionate impact suggests that a significant portion of Dishman’s cost base—particularly employee expenses (₹3,891 million) and depreciation (₹907 million)—is fixed or semi-fixed. Consequently, even modest delays in project billing, such as the CHF 10 million deferment, can erase profitability entirely. The strong performance in the Marketable Molecules segment (up 48%) was insufficient to offset the drag from the larger CDMO business, highlighting the company’s continued heavy reliance on complex, long-cycle CDMO contracts for overall financial health.

Balance Sheet and Outlook

Net debt excluding lease liabilities stood at CHF 153.6 million as on June 30, 2026, an increase from CHF 146.8 million as on March 31, 2026. Capital expenditure during the quarter was CHF 4.9 million. The company maintains a global manufacturing footprint across India, Switzerland, UK, France, China, and the Netherlands, with 23 multi-purpose facilities and 32 R&D labs. Investors will need to monitor subsequent quarters to determine if the deferred CDMO revenues materialize in H2FY27, which would be critical for restoring profitability trends established in FY26.